SCHEMBL7686534

SCHEMBL7686534

CC(C)(O)CC[C@H](C[C@@H](O)[CH]Cc1ccccc1Cl)C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 5/20 0.41
CHRM2 P08172 1/20 0.35
CCR5 P51681 1/20 0.35
ALDH1A1 P00352 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CTSK P43235 1/20 0.32
TSHR P16473 1/20 0.32
KCNJ6 P48051 1/20 0.32
KCNJ5 P48544 1/20 0.32
KCNJ3 P48549 1/20 0.32
LMNA P02545 3/20 0.32
IDO1 P14902 2/20 0.32
HTT P42858 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
TAAR1 Q96RJ0 2/20 0.32
SIRT2 Q8IXJ6 1/20 0.32
SIRT1 Q96EB6 1/20 0.32
MAP3K14 Q99558 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676710 0.91 CCR1 (0.34) CCR1ALDH1A1SLC6A2SLC6A4SLC6A3
SCHEMBL7688073 0.86 CCR1 (0.51) CCR1CHRM2CCR5ALDH1A1SLC6A2
SCHEMBL7686360 0.84 CCR1 (0.41) CCR1CHRM2CCR5LMNAHTT
SCHEMBL2676711 0.80 CCR1 (0.47) CCR1CHRM2CCR5ALDH1A1SLC6A2
SCHEMBL2676320 0.78 CCR1 (0.43) CCR1CHRM2CCR5ALDH1A1SLC6A2
SCHEMBL7687929 0.78 CCR1 (0.42) CCR1CHRM2CCR5
SCHEMBL7688715 0.77 CCR1 (0.37) CCR1CHRM2CCR5ALDH1A1TSHR
SCHEMBL2675799 0.76 REN (0.35) CCR1LMNAHTT
SCHEMBL27608396 0.76 CCR1 (0.51) CCR1CHRM2CCR5
SCHEMBL7688420 0.76 CCR1 (0.51) CCR1CHRM2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US disclosed